SK bioscience said on the 3rd that, on a consolidation basis, its operating loss in the third quarter of this year was 19.4 billion won, a reduced deficit compared with 39.6 billion won in the same period a year earlier, based on preliminary figures.
Third-quarter revenue was 150.8 billion won, up 144.6% from the same period a year earlier. Net income returned to the black at 21.1 billion won.
SK bioscience said it has continued top-line growth on the back of contributions from subsidiary IDT Biologika, acquired in Oct. last year, and sales of its own vaccines.
Cumulative revenue for the first to third quarters this year came to 467.2 billion won, more than quadrupling from the same period a year earlier, largely due to a focus on securing customers and expanding orders in Europe and North America after acquiring IDT.
It also noted that the cell-culture influenza vaccine SkyCellflu has been supplied since the start of the domestic inoculation season and exports to Southeast Asian markets such as Thailand and Malaysia are increasing, and that overseas supply of the varicella vaccine SkyVaricella is proceeding smoothly. Sanofi vaccines in distribution, including the hexavalent combination vaccine Hexaxim and the respiratory syncytial virus (RSV) preventive antibody injection Beyfortus, are also contributing to sales.
SK bioscience said that following more than 100 billion won in research and development (R&D) investment last year, it will further increase investment this year, continuing investment for future growth. The company said it plans to create sustained growth through commercialization of a pneumococcal vaccine, development of next-generation vaccines, and expansion of the global contract development and manufacturing organization (CDMO) business centered on IDT.